Highlight Therapeutics Dr Marisol Quintero joined Proactive's Stephen Gunnion with details of the “potentially game-changing” early results from the Phase 2b clinical trials of the company's lead drug in combination with a leading immunotherapy drug.
The Phase 2 study is testing Highlight’s BO-112 drug in combination with a leading anti-PD1 immunotherapy as a second-line treatment on 37 melanoma patients who have shown anti-PD1 resistance.
Quintero telling Proactive that the privately-owned company is now in the planning stage of a pivotal Phase 3 trial, due to begin in 2022, and is starting to talk to potential partners about other combinations.